← All drugs
Drug · FAERS side-effect profile with label screen

Pregabalin side effects: what 270,525 FDA adverse event reports show

Pregabalin · 1,171 reaction terms · 1,197,558 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

270,525 reports · 67% serious · 22,080 with death outcome · 66% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Pregabalin capsules are indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age an.

FDA label, Indications and Usage

What it is

Pregabalin is a gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer).

PubChem CID 5486971 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 3Labeled (related wording) 4Likely indication confounding 2Lab value / disease marker 7Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,131 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
C-reactive protein47585.2
74.7–97.1ROR 85.3 · calibrated p 4e-7 ✓
40.5 EB05 37.5 · IC025 +5.1
3/3 methods agree
Lab value / disease markerserious n=475 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Deep vein thrombosis postoperative88463.4
58.0–69.4ROR 63.6 · calibrated p 3e-6 ✓
34.9 EB05 33.0 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=884 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Lupus vulgaris47250.7
45.1–56.9ROR 50.8 · calibrated p 1e-5 ✓
30.7 EB05 28.4 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=472 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Anti-cyclic citrullinated peptide antibody24845.5
38.9–53.3ROR 45.6 · calibrated p 3e-5 ✓
28.7 EB05 25.8 · IC025 +4.6
3/3 methods agree
Lab value / disease markerserious n=248 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Swollen joint count increased1,07740.6
37.7–43.7ROR 40.8 · calibrated p 5e-5 ✓
26.7 EB05 25.4 · IC025 +4.6
3/3 methods agree
Lab value / disease markerserious n=1,076 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Neurologic neglect syndrome17635.2
29.5–42.1ROR 35.3 · calibrated p 1e-4 ✓
24.3 EB05 21.4 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=176 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Rheumatic fever1,15427.6
25.8–29.5ROR 27.7 · calibrated p 4e-4 ✓
20.5 EB05 19.5 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=1,154 · ♀ 100% (drug 66%) · 95% cliniciannot reported in cached trials
Facet joint syndrome79826.0
24.0–28.2ROR 26.1 · calibrated p 5e-4 ✓
19.6 EB05 18.5 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=794 · ♀ 100% (drug 66%) · 93% cliniciannot reported in cached trials
Adjustment disorder with depressed mood50725.8
23.3–28.5ROR 25.9 · calibrated p 6e-4 ✓
19.5 EB05 18.1 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=501 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Retinitis39323.6
21.1–26.5ROR 23.7 · calibrated p 9e-4 ✓
18.2 EB05 16.8 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=393 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
X-ray abnormal41223.0
20.6–25.7ROR 23.1 · calibrated p 0.001 ✓
17.9 EB05 16.5 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious n=411 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Amaurosis fugax24022.2
19.2–25.6ROR 22.2 · calibrated p 0.001 ✓
17.4 EB05 15.6 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=240 · 100% cliniciannot reported in cached trials
Substance use disorder68121.8
20.0–23.8ROR 21.9 · calibrated p 0.001 ✓
17.1 EB05 16.1 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=680 · ♀ 20% (drug 66%) · 100% cliniciannot reported in cached trials
Carotid artery thrombosis18921.8
18.6–25.6ROR 21.8 · calibrated p 0.001 ✓
17.1 EB05 15.2 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=189 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Dislocation of vertebra47821.0
19.0–23.2ROR 21.0 · calibrated p 0.002 ✓
16.6 EB05 15.4 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=478 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Rheumatoid factor positive1,21720.5
19.3–21.9ROR 20.6 · calibrated p 0.002 ✓
16.3 EB05 15.6 · IC025 +3.9
3/3 methods agree
Lab value / disease markerserious n=1,216 · ♀ 100% (drug 66%) · 95% cliniciannot reported in cached trials
Duodenal ulcer perforation1,29016.3
15.4–17.4ROR 16.4 · calibrated p 0.005 ✓
13.6 EB05 13.0 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious PRR 11.7 · ♀ 100% (drug 66%) · 95% cliniciannot reported in cached trials
Seronegative arthritis19115.7
13.5–18.4ROR 15.7 · calibrated p 0.006 ✓
13.1 EB05 11.6 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=191 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
C-reactive protein abnormal1,08115.6
14.6–16.6ROR 15.6 · calibrated p 0.006 ✓
13.1 EB05 12.4 · IC025 +3.6
3/3 methods agree
Lab value / disease markerserious n=1,079 · 91% cliniciannot reported in cached trials
Pre-existing condition improved1,03015.0
14.0–16.0ROR 15.0 · calibrated p 0.007 ✓
12.6 EB05 12.0 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=361not reported in cached trials
Fibromyalgia3,95214.9
14.4–15.4ROR 15.1 · calibrated p 0.007 ✓
12.6 EB05 12.3 · IC025 +3.6
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious PRR 11.3 · ♀ 92% (drug 66%)not reported in cached trials
Adjustment disorder20414.2
12.2–16.5ROR 14.2 · calibrated p 0.009 ✓
12.1 EB05 10.7 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=199 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Sleep disorder due to general medical condition, insomnia type97713.7
12.8–14.7ROR 13.8 · calibrated p 0.010 ✓
11.7 EB05 11.1 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=972 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Porphyria acute20613.4
11.6–15.6ROR 13.4 · calibrated p 0.011 ✓
11.5 EB05 10.2 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=206 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Helicobacter infection1,38912.1
11.4–12.8ROR 12.1 · calibrated p 0.016 ✓
10.5 EB05 10.1 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious PRR 9.6 · ♀ 100% (drug 66%) · 92% cliniciannot reported in cached trials
Sciatica2,11511.8
11.3–12.3ROR 11.9 · calibrated p 0.017 ✓
10.3 EB05 10.0 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious PRR 11.1 · ♀ 91% (drug 66%)NCT01256593: 1/3,613 (0.0%) on Pregabalin
Personality disorder33811.3
10.1–12.6ROR 11.3 · calibrated p 0.021 ✓
9.9 EB05 9.0 · IC025 +3.1
3/3 methods agree
Labeled adverse reaction
exact term
serious n=330 · ♀ 100% (drug 66%)not reported in cached trials
Bone erosion42610.5
9.5–11.6ROR 10.5 · calibrated p 0.028 ✓
9.3 EB05 8.5 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=425 · ♀ 100% (drug 66%) · 100% cliniciannot reported in cached trials
Post herpetic neuralgia17210.4
8.9–12.2ROR 10.4 · calibrated p 0.029 ✓
9.1 EB05 8.0 · IC025 +2.9
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
♀ 0% (drug 66%) · 100% consumernot reported in cached trials
Feeling drunk88410.3
9.6–11.0ROR 10.3 · calibrated p 0.029 ✓
9.2 EB05 8.7 · IC025 +3.1
3/3 methods agree
Labeled adverse reaction
exact term
serious n=512not reported in cached trials
Anti-cyclic citrullinated peptide antibody positive83810.2
9.5–11.0ROR 10.3 · calibrated p 0.030 ✓
9.1 EB05 8.6 · IC025 +3.1
3/3 methods agree
Lab value / disease markerserious PRR 7.9 · ♀ 100% (drug 66%) · 93% cliniciannot reported in cached trials
Folliculitis1,20810.1
9.6–10.8ROR 10.2 · calibrated p 0.030 ✓
9.0 EB05 8.6 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious PRR 9.1 · ♀ 100% (drug 66%) · 95% clinicianNCT01256593: 1/3,613 (0.0%) on Pregabalin
Diabetic neuropathy5589.7
8.9–10.6ROR 9.7 · calibrated p 0.036 ✓
8.6 EB05 8.1 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
serious n=399not reported in cached trials
Bradypnoea2889.2
8.1–10.4ROR 9.2 · calibrated p 0.043 ✓
8.2 EB05 7.5 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=288 · ♀ 39% (drug 66%) · 100% cliniciannot reported in cached trials
Radiculopathy2809.1
8.0–10.3ROR 9.1 · calibrated p 0.045 ✓
8.2 EB05 7.4 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=264 · ♀ 100% (drug 66%)NCT01256593: 1/3,613 (0.0%) on Pregabalin (serious AE)
Autoimmune disorder1,0149.1
8.5–9.7ROR 9.1 · calibrated p 0.044 ✓
8.2 EB05 7.8 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious PRR 7.6 · ♀ 100% (drug 66%)not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Dependence / withdrawal9,7282.62.6–2.7signal
Fall / fracture11,6652.42.4–2.5signal
Depression8,1502.32.2–2.3signal
Suicidality7,0242.32.2–2.3signal
Interstitial lung disease2,7052.22.1–2.3signal
Extrapyramidal2,5331.91.8–2.0raised
Rhabdomyolysis / myopathy1,8331.81.7–1.9raised
Hyponatraemia1,7541.71.6–1.8raised
Seizure4,1841.71.6–1.7raised
Opportunistic infection2,8611.61.6–1.7raised
Serious infection16,2031.61.6–1.7raised
Liver injury5,9871.51.5–1.6raised
Kidney injury8,5311.51.4–1.5raised
Hyperglycaemia / diabetes6,3671.41.4–1.5raised
Tendon disorder6791.41.3–1.5raised
Hypoglycaemia1,5411.31.2–1.3raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Pregabalin as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (4 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)26,9771.6
1.6–1.6ROR 1.7 · calibrated p 0.749
1.6 EB05 1.6 · IC025 +0.6Reporting / coding artifactage-adj. PRR 1.8 · serious PRR 2.0not reported in cached trials
Pain26,3313.4
3.4–3.5ROR 3.7 · calibrated p 0.442
3.3 EB05 3.3 · IC025 +1.7
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 3.5 · serious PRR 2.6NCT01220180: 2/4,174 (0.0%) on Pregabalin
Fatigue (tiredness)15,6351.6
1.5–1.6ROR 1.6 · calibrated p 0.710
1.6 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.9NCT01220180: 3/4,174 (0.1%) on Pregabalin
Dizziness14,8472.4
2.3–2.4ROR 2.4 · calibrated p 0.843
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.0 · serious PRR 2.4NCT01220180: 74/4,174 (1.8%) on Pregabalin
Nausea14,5091.4
1.4–1.5ROR 1.5 · calibrated p 0.614
1.4 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.8NCT01256593: 27/3,613 (0.7%) on Pregabalin
Off label use (used outside approved label)13,8011.2
1.2–1.3ROR 1.2 · calibrated p 0.473
1.2 EB05 1.2 · IC025 +0.3Reporting / coding artifactage-adj. PRR 1.4 · serious PRR 1.5not reported in cached trials
Headache13,0691.6
1.6–1.7ROR 1.7 · calibrated p 0.746
1.6 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 2.1NCT01220180: 1/4,174 (0.0%) on Pregabalin
Malaise (feeling unwell)12,8842.3
2.3–2.4ROR 2.4 · calibrated p 0.868
2.3 EB05 2.2 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.3 · serious PRR 2.2NCT01256593: 4/3,613 (0.1%) on Pregabalin
Somnolence (drowsiness)11,8234.8
4.7–4.9ROR 5.0 · calibrated p 0.239
4.6 EB05 4.5 · IC025 +2.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 4.4 · serious PRR 4.6NCT01220180: 69/4,174 (1.7%) on Pregabalin
Weight increased (weight gain)11,6214.2
4.1–4.3ROR 4.4 · calibrated p 0.317
4.0 EB05 4.0 · IC025 +2.0
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 3.6 · serious PRR 4.1NCT01220180: 1/4,174 (0.0%) on Pregabalin
Pain in extremity11,3943.1
3.0–3.1ROR 3.2 · calibrated p 0.575
3.0 EB05 2.9 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.7 · serious PRR 3.0NCT01256593: 2/3,613 (0.1%) on Pregabalin
Fall11,0402.6
2.6–2.7ROR 2.7 · calibrated p 0.733
2.6 EB05 2.5 · IC025 +1.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.4 · serious PRR 2.4NCT01256593: 4/3,613 (0.1%) on Pregabalin (serious AE)
Dyspnoea (shortness of breath)10,4591.4
1.4–1.5ROR 1.5 · calibrated p 0.615
1.4 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.5not reported in cached trials
Diarrhoea (diarrhea)10,1721.2
1.2–1.3ROR 1.2 · calibrated p 0.466
1.2 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.1 · serious PRR 1.4NCT01220180: 1/4,174 (0.0%) on Pregabalin
Insomnia (trouble sleeping)9,7292.9
2.8–3.0ROR 3.0 · calibrated p 0.637
2.8 EB05 2.8 · IC025 +1.5
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.8 · serious PRR 3.0NCT01220180: 1/4,174 (0.0%) on Pregabalin

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Pregabalin ↔ Oedema peripheral.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Pregabalin?

In FDA FAERS, the most frequently co-reported reaction terms for Pregabalin are pain, fatigue, dizziness, nausea, headache, malaise. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Pregabalin have an FDA boxed warning?

No. The FDA label retrieved for Pregabalin has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Pregabalin causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.